Number of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatments is Associated With Longer Survival
Rattachement africain : fr, sa. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To analyze the reasons for stopping pressurized intraperitoneal aerosolized chemotherapy (PIPAC) delivered for unresectable peritoneal surface malignancies (PSMs) and to determine survival in a large patient cohort of an experienced PIPAC center. BACKGROUND: PIPAC alone or combined with systemic chemotherapy was developed to palliatively treat unresectable PSM. Safety, tolerance, and promising survival results were already reported, but the reasons for stopping treatment remain unclear, and the influence of the number of PIPAC procedures on prognosis has not been evaluated. METHODS: A retrospective analysis of PIPAC procedures from a prospectively maintained single-institution PSM database was conducted from January 2016 to January 2023. RESULTS: A total of 346 patients underwent 1200 PIPAC treatments in the defined time period. Two-thirds of the patients completed 3 or more PIPAC procedures, and 2 patients had more than 15 treatment procedures. Reasons for PIPAC cessation were disease progression or complication (56%), reorientation to a potential curative procedure (19%), surgical complications of the procedure (13%), death between procedures (8%), and patient request (3%). PSM origin and receiving 3 or more PIPAC treatments were independently correlated with better survival in the overall population, in the group of ultimately unresectable PSM, and after propensity score weighting. CONCLUSIONS: The main reason for stopping PIPAC treatment in the palliative management of PSM is disease progression. When 3 or more PIPAC procedures can be delivered in combination with systemic chemotherapy, survival is significantly improved. Its use should be validated by prospective studies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Number of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatments is Associated With Longer Survival
- Date Crossref
- 23/07/2024
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hôpital Lyon Sud pays non établi dans la noticeÉtablissement de santé
-
Lyon 1 Université pays non établi dans la noticeUniversité ou école supérieure
-
Centre pour l'innovation en cancérologie de Lyon pays non établi dans la noticeStructure de recherche
-
King Khaled Hospital pays non établi dans la noticeÉtablissement de santé
-
Lyon Sud University Hospital Department of General Surgery and Surgical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Lyon 1 University EA 3738 CICLY pays non établi dans la noticeUniversité ou école supérieure
-
King Khalid Hospital Department of General Surgery and Surgical Oncology pays non établi dans la noticeÉtablissement de santé
Hôpital Lyon Sud, Lyon 1 Université et Centre pour l'innovation en cancérologie de Lyon, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.